2024-10-16
September 26, 2024, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") self-developed product Procaterol Hydrochloride Oral Solution (trade name: 贝舒清®) has been successfully approved by the Chinese CDE, and Beimei Pharmaceutical is the MAH of this product.
Procaterol Hydrochloric Oral Solution is a respiratory medication used to alleviate symptoms such as respiratory distress caused by obstructive airway disorders, such as bronchial asthma, chronic bronchitis, acute bronchitis, and asthmatic bronchitis.
Procaterol is a third-generation, long-acting β adrenergic receptor agonist with high selectivity for β2 receptors in bronchial smooth muscle. It only requires 1-2 doses per day to effectively relieve cough, asthma, and phlegm.
The Procaterol Hydrochloride Oral Solution has a rapid onset of action, is easy to take, and has a sweet taste, making it particularly suitable for children, the elderly, and people with swallowing difficulties.
About Beimei Pharma
Shenzhen Beimei Pharmaceutical Co., Ltd. ("Beimei Pharma") focuses on the field of pediatric prescription medicines, integrating full-spectrum capabilities of R&D, manufacture, commercialization and global cooperation, driven by the core strategy of self-development and global collaboration via in-licensing, asset purchase acquisition etc. Synergizing with the manufacture base in Liangyungang to fulfil sufficient production and global supply of diversified special formulations for children's medications, Beimei is aiming to provide pediatric patients with high-quality and full range of drugs.
Beimei Pharma has more than 40 pediatric drug products in portfolio and pipeline, including 5 approved drugs launched in the market, and several innovative drugs with global rights and independent intellectual property rights. The current pipeline covers the therapeutic fields of dermatology, respiratory, gastroenterology, anti-infection, neurology, neonatal, endocrinology, etc.
Beimei Pharma has established long-term partnerships with multiple large international pharmaceutical companies, such as Hetero, Cipla, Deva, Dr. Reddy’s, LTS, MedPharma, Synthon, EMP, NTC, Syrimed, etc.
Beimei Pharma has completed the Angel Round, Round A, Round B/B+ and Round C financing with hundreds of millions of RMB. Beimei Pharma gained recognition from many well-known investment institutions, including Efung Capital and the industrial parties.
For additional information, please visit the website: http://www.beimeiyaoye.com/
